A

Akebia Therapeutics
D

AKBA

1.79500
USD
-0.11
(-5.53%)
Market Closed
Volume
152,706
EPS
-0
Div Yield
-
P/E
-8
Market Cap
391,635,258
OverviewSignalsIdeasNews
Related Instruments
    A
    AGEN
    -0.11500
    (-3.34%)
    3.33000 USD
    D
    DVAX
    0.000
    (0.00%)
    13.335 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    K
    KPTI
    -0.00940
    (-1.55%)
    0.59840 USD
    K
    KURA
    0.11500
    (1.41%)
    8.26500 USD
    M
    MGNX
    -0.13000
    (-4.50%)
    2.76000 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    More
News

Title: Akebia Therapeutics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease,in adult patients, HIF-PH inhibitors in preclinical development.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.